Review of Clinical Pharmacology and Pharmacokinetics - International Edition最新文献

{"title":"Network pharmacology speaking to ethnopharmacology: new data on an ancient remedy","authors":"Junying Liu","doi":"10.61873/zxqs4380","DOIUrl":"https://doi.org/10.61873/zxqs4380","url":null,"abstract":"Network pharmacology as a “green approach”, predicting metabolite behaviours chemically and biologically and guid¬ing biological experimental design, is a new strategy aiming to uncover the mechanism of action of natural products as drug candidates. It provides a powerful way to identify novel mechanisms of natural products with potential thera¬peutic effects. This approach has emerged as a powerful tool to overcome the limitations of traditional methods, such as the ability to predict the adverse effects of a drug and the likelihood of failure during clinical trials, by applying systems biology principles to the field of pharmacology. This method combines the multi-omics dataset, computer modeling, and chemical biology so as to reveal pharmaceutical actions and guide drug discovery. Therefore, computer-aided drug design combined with network pharmacology can be viewed as a novel in silico screening ap¬proach to drug discovery, by utilising chemoinformatics, bioinformatics, structure biology, and chemical biology. This strategy includes target-based virtual screening - molecular docking, ligand similarity-based virtual screening, and inverse screening (Inver-dock), providing a powerful tool for target identification of drug candidates, multitarget dis¬covery, and natural bioactive product profiling. It can also be used for selectivity profiling of drugs, drug repositioning, safety profiling, and metabolism profiling prediction (ADMET).","PeriodicalId":515365,"journal":{"name":"Review of Clinical Pharmacology and Pharmacokinetics - International Edition","volume":"38 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141011548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the CO2 water bath therapy effectiveness on diabetic foot ulcers through VEGF and TNF-α levels","authors":"Ghazwan Riyad Abdulhamza, Najeeb Hassan Mohammed","doi":"10.61873/onpk3289","DOIUrl":"https://doi.org/10.61873/onpk3289","url":null,"abstract":"Vasculopathy is typically seen in diabetic patients, and can lead to foot ulcerations. Carbon dioxide (CO2) therapy was found to improve chronic wound healing in patients with vascular impairment. This type of therapy refers to the transcutaneous and subcutaneous application of CO2 as well as CO2 water baths for therapeutic purposes. In the method used herein, artificial CO2-containing water for foot bathing was generated by dissolving Carbothera® (MRE-SPA-MD; Mitsubishi Rayon Engineering, Tokyo, Japan) and generating CO2 (free CO2 concentration: 1,000–1,200 mg/L; pH 4.6). The foot of each patient was immersed in CO2-enriched water (depth of 20–30 cm, 37–38°C, 30-min duration) three times per week, for the next three months. Dramatic clinical improvement was observed in the CO2 water bath therapy group before and after the treatment, while both the blood levels of the vascular endothelial growth factor and of the tumour necrosis factor-alpha in these patients exhibited significant changes. The advantages of this method are the absence of pain and the protection against infection, while the improved angiogenesis and oxygena¬tion can result in healing of the chronic wound.","PeriodicalId":515365,"journal":{"name":"Review of Clinical Pharmacology and Pharmacokinetics - International Edition","volume":"350 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141011936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of COVID-19 vaccination against a SARS-CoV-2 reinfection in the Babil Province","authors":"F. A. Alzubaidi, E. Oubaid, Zahraa I. J. Shubber, Hussam W. Al-Humadi, Rafal J. Al-Saigh","doi":"10.61873/svrl5228","DOIUrl":"https://doi.org/10.61873/svrl5228","url":null,"abstract":"Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has been documented all over the world. Currently, limited evidence exists concerning the protec¬tion afforded by the COVID-19 vaccination against reinfection with SARS-CoV-2. This case-control study was per¬formed in order to assess the association between COVID-19 vaccination and SARS-CoV-2 reinfection in the Babil Province; the study used an electronic questionnaire. The infected patients were 115 (aged ≥18 years) and were confirmed by a positive PCR and/or a CT scan, they were either fully vaccinated or not with a second dose of a (Pfizer, AstraZeneca, or Sinopharm) vaccine before the reinfection date, and they were compared with 300 control partici¬pants. The study’s findings revealed that the unvaccinated individuals had 4.5 times the odds of reinfection compared to those who were fully vaccinated, without preference for the manufacturer of the vaccine. The conclusion suggests that getting fully vaccinated against COVID-19 can significantly reduce the likelihood of reinfection, can enhance overall protection, and can minimize the risk of future infections.","PeriodicalId":515365,"journal":{"name":"Review of Clinical Pharmacology and Pharmacokinetics - International Edition","volume":"307 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141012403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 1st International Babylon Conference on Clinical and Experimental Pharmacological Research: mapping the Iraqi pharmacological research activity and priorities","authors":"Charis Liapi, Apostolos Zarros","doi":"10.61873/vbnu2182","DOIUrl":"https://doi.org/10.61873/vbnu2182","url":null,"abstract":"The proceedings of the 1st International Babylon Conference on Clinical and Experimental Pharmacological Research (taking place at the College of Pharmacy of the University of Babylon, in Hillah, Iraq; May 4-5, 2024) are hereby hosted by the Review of Clinical Pharmacology and Pharmacokinetics – International Edition; a journal that has provided a significant service to the international pharmacological community since 1987. These proceedings include a total of 50 papers (including this editorial) and provide a representative overview of the conference’s rich scientific pro¬gramme. The latter has served two objectives: (i) to facilitate the mapping of the Iraqi pharmacological research and priorities, and (ii) to enable the establishment of international collaborations in the field. In that respect, the proceed¬ings host the inspiring messages of several conference keynote speakers from abroad, and feature a variety of clinical and experimental studies that well relate to the priorities currently set by the Iraqi pharmacological community.","PeriodicalId":515365,"journal":{"name":"Review of Clinical Pharmacology and Pharmacokinetics - International Edition","volume":"337 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141011983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatotoxic effects of Stevia rebaudiana leaf extract and commercial stevia on rats: a comparative study","authors":"Aamer Mousa Ali, Noor Ali Hussein, Dhafer Jawad, H. H. Abed, Shereen M. Mekkey","doi":"10.61873/xfaq5379","DOIUrl":"https://doi.org/10.61873/xfaq5379","url":null,"abstract":"The popularity of stevia is high, especially among diabetics and those looking to reduce their calorie-intake. The aim of this study was to compare the effects of a commercially-available stevia and of a Stevia rebaudiana leaf extract on the liver function and histology of rats. After preparing the Stevia rebaudiana leaf extract, 60 healthy adult male rats were randomly separated into three groups: untreated control, commercial stevia treatment (25 mg/kg), and Stevia rebaudiana leaf extract treatment (25 mg/kg). Our results show that after 60 days of treatment (oral administration), a significant elevation of the alanine aminotransferase (ALT) levels was observed in the commercial stevia-treated group, suggesting potential effects on liver function. The Stevia rebaudiana leaf extract-treated group also exhibited increased ALT levels. Moreover, the aspartate aminotransferase (AST) levels were found significantly increased in both of these treatment groups (when compared to the control group). Alkaline phosphatase levels were not found altered between groups. Histological-examinations, in spite of the elevated ALT and AST levels, exhibited no abnor¬malities in the liver. Although stevia is generally regarded as safe, this study underlines the importance of considering the type and form of stevia when evaluating its effects on liver health. Further study is warranted so as to elucidate the specific components and mechanisms responsible for the observed variations in liver enzymes, and to confirm the overall safety of stevia products.","PeriodicalId":515365,"journal":{"name":"Review of Clinical Pharmacology and Pharmacokinetics - International Edition","volume":"232 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141012853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel anticancer mechanisms of JinYingZi-derived oleanolic acid against renal cell carcinoma: an in silico analysis","authors":"Ismael Obaidi, F. A. Alzubaidi, Aymen A. Bash, Q. J. Fadheel, Hussam W. Al-Humadi, Junying Liu","doi":"10.61873/kzws3688","DOIUrl":"https://doi.org/10.61873/kzws3688","url":null,"abstract":"Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for 90% of all estimated cases. Advanced RCC often carries poor prognosis due to its high metastases rate, the lack of early-warning signs, as well as its complex clinical manifestations and its resistance to chemotherapy. Ethnopharmacologically, Fructus Rosae laevigata (JinYingZi) has been employed by Chinese medicine to treat various urinary tract and gastrointestinal dis¬orders. This study aimed at performing a series of mechanistic analyses in order to unlock the anticancer potential of JinYingZi-derived bioactive components against RCC. Several network pharmacology tools were employed so as to analyse the drug-disease interactions. Our data revealed that more than 2,214 genes were dysregulated in RCC, whereas the JinYingZi-derived bioactive compounds modulated 347 genes. The intersecting between RCC and the bioactive compounds revealed 132 cross targets. Our results were further validated by conducting molecular docking, which revealed a stable association between oleanolic acid with each of the following targets: androgen receptor (AR), dipeptidyl peptidase (DPP), estradiol (ESR1), nitric oxide synthase 2 (NOS2), and cyclooxygenase-2 (PTGS2). Our approach is being used successfully in order to evaluate a panel of novel medicinal plant-derived bioactive com¬pounds, and may lead to the identification of safe and effective chemical scaffolds that could act as templates for drug discovery or yield potential drug candidates.","PeriodicalId":515365,"journal":{"name":"Review of Clinical Pharmacology and Pharmacokinetics - International Edition","volume":"22 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141012039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse Effects of Long-term Proton Pump Inhibitors in Chronic Liver Disease Patients – A Preliminary Article Review","authors":"U. Maimunah, Andreas Agung Kurniawan, Andrio Palayukan","doi":"10.61873/wway6273","DOIUrl":"https://doi.org/10.61873/wway6273","url":null,"abstract":"Background: Proton pump inhibitors (PPIs) are widely prescribed medications for the management of gastroesophageal reflux disease (GERD) and peptic ulcer disease. Despite their efficacy, concerns have emerged regarding their potential adverse effects, particularly in patients with chronic liver disease (CLD). CLD patients often experience gastrointestinal symptoms and may be prescribed PPIs, but the impact of PPI use on liver function and disease progression remains uncertain. Scope: This study aims to evaluate the adverse effects of PPIs on CLD patients through a review of available literature. The scope encompasses a review of studies examining the association between PPI use and liver-related outcomes, including hepatic encephalopathy, hepatic decompensation, liver cirrhosis progression, and mortality, among CLD patients. Method: A scoping review of relevant literature were conducted to identify studies investigating the adverse effects of PPIs in CLD patients. Databases including PubMed and Google Scholar were searched for articles published up to January, 1 2023. Eligible studies were selected based on predefined inclusion criteria. Results: The review identified 27 studies meeting the inclusion criteria, comprising observational studies and meta-analysis. The review revealed a significant association between PPI use and adverse liver outcomes in CLD patients. Specifically, PPI use was associated with increased risk of SBP based on studies reviewed, while other complications remained inconclusive. Conclusion: The findings suggest that PPI use may have detrimental effects on disease progression in CLD patients, Long-term use of PPIs can lead to higher risk of SBP in CLD patients. Clinicians should exercise caution when prescribing PPIs to this vulnerable population and consider alternative treatment options or minimize PPI use to mitigate potential adverse outcomes. Further research is warranted to elucidate the underlying mechanisms, confirm the effect of PPIs toward other complications of CLD and establish guidelines for PPI use in CLD patients.","PeriodicalId":515365,"journal":{"name":"Review of Clinical Pharmacology and Pharmacokinetics - International Edition","volume":" 16","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140684252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomedical applications of collagen: A Review","authors":"Mashiur Rahman, M. Huda, Anamul Hasan, Mala Khan","doi":"10.61873/kjdf4893","DOIUrl":"https://doi.org/10.61873/kjdf4893","url":null,"abstract":"Collagen is an excellent biomaterial. Biological characteristics of collagen including biodegradability and weak antigenicity made it a primary resource in medical application. In biomedical field collagen is mainly used as sponges for wound/burn, supplement in rheumatoid arthritis, drug delivery system, controlling material for transdermal delivery and basic matrices for cell culture system due to its ability to stimulate formation of tissue and organ. Moreover, collagen is also applied in tissue engineering including bone defect, tissue regeneration, skin replacement and artificial blood vessels and valves. The article reviews biomedical application of collagen in wound healing, rheumatoid arthritis, drug delivery system, tissue engineering and lung function improvement in pulmonary fibrosis due to viral infection.","PeriodicalId":515365,"journal":{"name":"Review of Clinical Pharmacology and Pharmacokinetics - International Edition","volume":"43 S1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140723773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple sclerosis’ evolution of paediatric patients in adult life: A preliminary study","authors":"Danai-Niki Giourgali","doi":"10.61873/jtuw4404","DOIUrl":"https://doi.org/10.61873/jtuw4404","url":null,"abstract":"Background - Nowadays, multiple sclerosis is considered to be the most common immune-mediated, inflammatory, demyelinating disease of the central nervous system. Approximately 2.1 million people suffer from this disease world- wide. Scope - The presented article is a retrospective observational preliminary clinical study, being based upon fourteen patients. Materials and methods – These patients were initially evaluated and diagnosed in the ‘Neuropaediatric department’ and then admitted to the ‘Emergency University Hospital of Bucharest’ (SUUB), after the age of 18 years. The aim of this clinical study was to retrospectively assess the evolution of multiple sclerosis from the moment of its initial clinical manifestation on these paediatric patients into adult life. Results - For each of these patients, a study sheet was designed, according to which every patient was evaluated based upon a variety of parameters. Conclusions – The majority of the data obtained from this preliminary clinical study is congruent with the literature. Nevertheless, the presented article emphasizes the possibility of a Cytomegalovirus (CMV) - viral infection to be a causative agent of multiple sclerosis and not a protective factor instead. Even though epileptic seizures are considered to be an unusual manifestation of multiple sclerosis, a specific case of one paediatric patient with multiple sclerosis is being presented, who also suffered from general tonic-clonic seizures.","PeriodicalId":515365,"journal":{"name":"Review of Clinical Pharmacology and Pharmacokinetics - International Edition","volume":"76 24","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140377931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lutein in chronic diseases: A mini review","authors":"Maria Trapali","doi":"10.61873/ybcs9028","DOIUrl":"https://doi.org/10.61873/ybcs9028","url":null,"abstract":"Lutein is a xanthophyll carotenoid that can be found in a divergency of fruits and plants. Its main action is to protect eye health and vision. Its antioxidant properties play a crucial role in eye agitations, in decreasing inflammation, in protecting the neural tissues from chemical analyzed hypoxia and cell apoptosis. Lutein supplementation in associa- tion with low-calorie diet had a notable abatement in fat-free mass, visceral fat and serum levels of total cholesterol and LDL (low-density lipoprotein)-cholesterol. Lutein may also have a natural anti-cancer effect. This is because foods rich in lutein have antioxidant activity and oppose inflammation and oxidative stress. The aim of this mini-review was to provide an up-to-date overview of the main effects of lutein in health and disease.","PeriodicalId":515365,"journal":{"name":"Review of Clinical Pharmacology and Pharmacokinetics - International Edition","volume":"11 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140381532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}